Aurobindo Pharma Ltd
1,571.70
INR
-39.20
(-2.43%)
ISIN
INE406A01037
Return %
Stock
S&P 500
1Y
43.00
14.39
3Y
79.66
81.42
5Y
126.13
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Kambam Nithyananda Reddy
- Full Time Employees
- 46,455
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Galaxy, Plot No. 1 Hyderabad TS India 500032
- IPO Date
- Jan 19, 1995
- Website
- aurobindo.com
- Similar Companies
- Business
- Aurobindo Pharma Limited, headquartered in Hyderabad, India, and founded in 1986, develops, manufactures, and markets generic pharmaceuticals, active pharmaceutical ingredients (APIs), formulations, biosimilars, and injectables across therapeutic areas including antibiotics; anti-retrovirals; cardiovascular; central nervous system; gastroenterologicals; anti-allergics; oncology and hormones; dermatology; respiratory; peptides; vaccines; neurosciences; anti-diabetics; and cephalosporins. The company operates 29 manufacturing facilities worldwide with capacities exceeding 50 billion formulation units and 19,000 metric tons of APIs annually, serving over 150 markets including the US, Europe, and growth markets; it ranks among the top generic providers in eight European countries and maintains US headquarters in East Windsor, New Jersey, with marketing partners such as Pfizer and AstraZeneca. Aurobindo Pharma lists on Indian stock exchanges under the ticker AUROPHARMA.NS and derives over 70% of revenues from international operations, supported by robust R&D with 876 ANDA filings in the US, 600+ approvals, and significant investments at 5% of sales focused on biosimilars and specialty products. In recent developments, Aurobindo Pharma acquired US-based Lannett Company LLC for $250 million through its subsidiary Aurobindo Pharma USA Inc., enhancing US manufacturing capabilities in non-opioid controlled substances and ADHD therapeutics while mitigating tariff risks; it finalized full ownership of GLS Pharma in early 2025 by purchasing the remaining 49% stake to bolster its oncology pipeline. The company pursues a potential acquisition of Zentiva, valued at $5-5.5 billion, to expand its European footprint amid €1 billion revenue targets for FY26, alongside biosimilar advancements including European Commission approvals for three products like trastuzumab, MHRA UK nods for four including bevacizumab and trastuzumab, and Phase 3 successes for Prolia and Xolair biosimilars. Additional strategic moves encompass capacity expansions in Pen-G, injectables, and biologics CMO via TheraNym's collaboration with Merck & Co. for new bioreactor lines by FY28; Q2FY26 filings of 13 US ANDAs with seven approvals and six launches; and EBITDA margins of 20-21% driven by Europe growth, China plant ramp-up, and in-house manufacturing exceeding 50% of formulations.